您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > GSK2838232
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
GSK2838232
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
GSK2838232图片
CAS NO:1443461-21-9
包装与价格:
包装价格(元)
5mg电议
25mg电议

产品介绍
GSK2838232 在广泛的 HIV-1 分离株中抑制 HIV 逆转录酶活性,从专利 WO/2013090664A1 中提取,化合物 51。
Cas No.1443461-21-9
Canonical SMILESCC(C(C(C[C@@]([C@](O)([H])CN(CC1=CC=C(Cl)C=C1)CCN(C)C)2CC[C@]34C)=O)=C2[C@@]3([H])CC[C@]5([H])[C@]6(CC[C@@](OC(CC(C)(C(O)=O)C)=O)([H])C(C)(C6([H])CC[C@]54C)C)C)C
分子式C48H73ClN2O6
分子量809.56
溶解度DMF: 1 mg/ml,DMSO: 1 mg/ml,Ethanol: 1 mg/ml,Ethanol:PBS (pH 7.2) (1:3): 0.25 mg/ml
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

GSK2838232 is an HIV-1 maturation inhibitor [1] [2].

HIV-1 maturation inhibitors disrupt the cleavage of the HIV-1 gag protein immediate precursor by the enzyme HIV-1 protease. Maturation inhibitors bind the gag protein, which leads to the formation of immature, noninfectious virus particles incapable of infecting other cells. Also, maturation inhibitors inhibit HIV infections with resistance.

GSK2838232 is a HIV-1 maturation inhibitor and is active against a broad range of isolates, including those resistant to bevirimat [1]. GSK2838232 was developed for the treatment of chronic HIV infection. A phase I study in HIV-negative individuals had been completed. Single doses of 5, 10 or 20 mg GSK2838232 were used to evaluate the initial safety, tolerability, pharmacokinetics profile, and the effects of food and ritonavir on GSK2838232’s bioavailability and pharmacokinetics [2].

References:
[1].  Olender SA, Taylor BS, Wong M, et al. CROI 2015: Advances in Antiretroviral Therapy. CROI 2015 Highlights: Antiretroviral Therapy Volume 23 Issue 1 March/April 2015.
[2].  Horn T, Collins S. The Antiretroviral Pipeline. Antiretrovirals, 2014 PIPELINE REPORT.